Hung Trinh, Senior VP of Operations at Seneca Therapeutics, shared a post on LinkedIn about a recent article by Andrea Spinazzola et al, published in Frontiers in Immunology:
“Current landscape of T-cell engagers in early-phase clinical development in solid cancers
The most successful applications of immunotherapies involve monoclonal antibodies that block immunomodulatory molecules known as immune checkpoints, as well as chimeric antigen receptor-T (CAR-T) cells, which consist of engineered autologous T cells expressing a synthetic receptor against a TAA. While CAR-T cells offer a targeted therapeutic approach against cancer, immune checkpoint inhibitors (ICIs) work in part by inducing a robust generalized activation of T cells.
Additional strategies that have been comprehensively explored, with mixed results, include vaccines targeting TAAs and the use of tumor-infiltrating lymphocytes (TILs). Although immunotherapies have proven highly effective in prolonging the survival of patients with cancer, this benefit is generally restricted to only a subset of patients and to specific cancer types, and the extent of survival gain varies depending on the indication.”
Title: Current landscape of T-cell engagers in early-phase clinical development in solid cancers
Authors: Andrea Spinazzola, Giovanni Maria Iannantuono, James L. Gulley, Elena Giudice, Marco Filetti, Stefano Sganga, Francesca Lo Bianco, Charalampos S. Floudas, Gennaro Daniele
Read the Full Article on Frontiers in Immunology
More posts featuring Hung Trinh.